The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization

banner

Suven Life Sciences secures Two (2) Product Patents in Europe and Macau

29-Dec-2015 | Source : AG-IP News | Visits : 3731
HYDERABAD, INDIA - Suven Life Sciences Ltd (Suven) announced today in a press release that the grant of one (1) product patent from Europe (2519514) and one (1) product patent from Macau (J/001808) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2030 and 2029.

The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).

With these new patents, Suven has a total of twenty (20) granted patents from Europe and eight (8) granted patents from Macau. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally” says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer’s disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.
 
share



Related Articles